TotalMarketCap

Myriad Genetics

MYGNNasdaq United StatesHealth CareBiotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$597.332 M

$6.25 +3.74%

Close of 6 Nov 2026

As of 6 Nov 2026, Myriad Genetics (MYGN) has a market capitalization of $597.3M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$824.5M

#1627 by revenue

Earnings

-$366.0M

Loss-making

Shares outstanding

95,922,196

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →
  1. #7QuidelOrthoQDEL$886.3M
  2. #8Achieve Life SciencesACHV$658.1M
  3. #9Myriad GeneticsMYGN$597.3M
  4. #10Anbio BiotechnologyNNNN$529.5M
  5. #11Alpha TeknovaTKNO$484.9M

What if Myriad Genetics were worth as much as…

Open the what-if tool →

Gold $28.2T

$295,211.49

Per share 47,272× higher

Bitcoin $1.53T

$15,973.38

Per share 2,558× higher

Apple $5.02T

$52,439.11

Per share 8,397× higher

Or at a round number

$1.00B$2.00B$5.00B$10.0B

Where these numbers come from

Share counts and financials for Myriad Genetics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.